Hanlikang (rituximab biosimilar) / Fosun Pharma, Eurofarma, Farma de Colombia, Abbott, Shanghai Henlius Biotech - LARVOL DELTA

Rapid and deep clinical responses to HLX79 (E-602), a first-in-class human sialidase-Fc fusion protein, plus HLX01, a rituximab biosimilar, in patients with membranous nephropathy: a Ph2 trial (ACR Convergence 2026) - P2 | "Blinded interim Ph2 data in pMN demonstrate early, rapid, and deep proteinuria reductions with HLX79 (20 and 30 mg/kg) + RTX, exceeding historical RTX responses. The combination was well-tolerated. The data suggest potential improvements in speed and depth of responses with the addition of HLX79 to RTX SoC."

Clinical • Fibrosis • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Renal Disease • CD163

A retrospective study of the efficacy and safety of rituximab biosimilar for the treatment of membranous nephropathy. (PubMed, BMC Pharmacol Toxicol) - "Rituximab biosimilar has acceptable efficacy and safety in patients with MN, and their outcomes are similar to those of innovator RTX products reported in the literature. Thus, it may be used as an alternative to the innovator RTX as a first-line treatment for MN."

Journal • Retrospective data • Dermatology • Glomerulonephritis • Hypotension • Pruritus • Renal Disease

On April 9, 2026, Henlius…announced that the supplemental application for two new indications under non-Hodgkin's lymphoma of HANLIKANG (rituximab), independently developed and manufactured by the company, was approved by the National Medical Products Administration (NMPA). (Henlius Press Release) - "The key Phase 3 HLX01-NHL03 study results were officially published in the international authoritative journal BMC Cancer in January 2024....The two newly approved indications in China are: 1. In combination with polatuzumab vedotin, cyclophosphamide, doxorubicin, and prednisone for the treatment of previously untreated adult patients with DLBCL. 2. In combination with bendamustine and polatuzumab vedotin for the treatment of adult patients with relapsed or refractory DLBCL who are not candidates for hematopoietic stem cell transplant. covering both first-line and relapsed/refractory key therapeutic nodes in DLBCL."

China approval • Diffuse Large B Cell Lymphoma

Product Revenue Reaches New High, Driven by a Synergistic Commercial Portfolio (The Manila Times) - "Pursuant to agreements with its partners, the Company generated RMB 0.6117 billion in sales and licensing revenue from HANLIKANG (rituximab), up 11.1% year-on-year...two dosage strengths of HLX14 (denosumab) were approved in the United States, the European Union, and the UK under the trade names BILDYOS (60 mg/mL) and BILPREVDA (120 mg/1.7 mL), respectively, and were recently approved in Canada under the trade names BILDYOS and TUZEMTY, becoming the first 'China-developed' denosumab to approved in ex-China markets."

Sales • Chronic Lymphocytic Leukemia • Giant Cell Tumor of Bone • Hodgkin Lymphoma • Osteoporosis

Long-term outcomes of a novel initial regimen: Rituximab plus pegylated interferon α-2b in untreated advanced indolent B-cell lymphoma – 5-year follow-up of the ripple study (ASH 2025) - P2 | "Induction therapy consisted of rituximab biosimilar (Henliritux®; 375mg/m² IV on day 1) plus Peg-IFN-α2b (Pegberon®; 135μg SC on days 1 and 8) every 21 days for 6 cycles.Responders received maintenance (rituximab every 8 weeks; Peg-IFN-α2b monthly) for ≤2 years. Rituximab biosimilar with Peg-IFN-α2b demonstrates durable efficacy and manageabletoxicity in treatment-naïve iBCL, particularly in FL and MALT subtypes. Absence of HBV reactivationsuggests potential synergism between Peg-IFN-α2b and entecavir in HBV suppression. These resultssupport further evaluation in larger randomized trials."

Metastases • B Cell Lymphoma • Extranodal Marginal Zone Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Hepatitis B • Hepatitis C • Hepatology • Immune Modulation • Immunology • Indolent Lymphoma • Infectious Disease • Lymphoma • Lymphoplasmacytic Lymphoma • Marginal Zone Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Small Lymphocytic Lymphoma • Thrombocytopenia • Waldenstrom Macroglobulinemia • IFNA1

Novel Chemotherapy-Free Initial Treatment of Rituximab Biosimilar Plus Pegylated Interferon α-2b in Pts with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Results of the Ripple 3-Year Follow-up Study (ASH 2023) - P2 | "During induction phase, pts received rituximab biosimilar (Henliritux® Shanghai Henlius Biotech) 375 mg/m2 intravenous infusion on d1. Peg-IFN-α2b (Pegberon®, Xiamen Amoytop Biotech) was given at a dose of 135ug, subcutaneously, on d1,8...Simultaneously, CHB pts orally treated with entecavir continuously... Rituximab biosimilar plus pegylated interferon α-2b provided favorable response in newly diagnosed advanced iBCL with mild toxicity. No hepatitis B virus reactivation was observed."

Clinical • Metastases • Anemia • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Fatigue • Follicular Lymphoma • Hematological Malignancies • Hepatitis B • Hepatology • Indolent Lymphoma • Infectious Disease • Lymphoma • Lymphoplasmacytic Lymphoma • Marginal Zone Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Small Lymphocytic Lymphoma • Thrombocytopenia • Waldenstrom Macroglobulinemia • IFNA1

A Randomized, Controlled, Multicenter, Phase 2 Clinical Study Evaluating the Efficacy, Safety, and Tolerability of HLX79 Combined with a Rituximab Biosimilar in Patients with Active Glomerulonephritis (KIDNEY WEEK 2025) - P1/2 | "This study aims to evaluate the efficacy, safety, and tolerability of HLX79 in combination with a RTX biosimilar (HANLIKANG) in patients with active glomerulonephritis. The primary endpoints in Part B are the proportion of MN patients achieving complete or partial remission at week 24 of treatment and the proportion of LN patients achieving PERR at week 24 of treatment. With Guangdong Provincial People’s Hospital as the lead site, 17 sites in China are participating in the study, and patient enrollment has commenced."

Clinical • P2 data • Fibrosis • Glomerulonephritis • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease

Cost-effectiveness of HLX01 (Hanlikang®) vs. rituximab combined with CHOP in treatment-naive diffuse large B-Cell lymphoma: a partitioned survival model analysis. (PubMed, Front Pharmacol) - "This study evaluates the cost-effectiveness of Hanlikang (HLX01), a biosimilar of rituximab, compared to rituximab (MabThera), both combined with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen, for treatment-naive diffuse large B-cell lymphoma (DLBCL) patients. Hanlikang offers a cost-effective alternative to rituximab in specific patient populations, particularly those not eligible for transplant. However, its economic benefits diminish in more complex treatment scenarios, such as those involving CAR-T therapy or novel agents."

HEOR • Journal • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

Cost-Effectiveness of HLX01 (Hanlikang) vs. Rituximab Combined with CHOP in Treatment-Naive Diffuse Large B-Cell Lymphoma: A Partitioned Survival Model Analysis (Front Pharmacol) - "Over 10 years, Hanlikang-CHOP (H-CHOP) patients gained 7.11 QALYs, compared to 6.50 QALYs for Rituximab-CHOP (R-CHOP). The ICER for transplant-eligible patients ranged from US$ 36,386.92 (CNY 263,215.70) to US$ 38,379.79 (CNY 277,631.72) per QALY, depending on the treatment."

HEOR • Diffuse Large B Cell Lymphoma

A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Shanghai Henlius Biotech

New P2 trial • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease

NOVEL CHEMOTHERAPY-FREE INITIAL TREATMENT OF RITUXIMAB PLUS PEGYLATED INTERFERON Α-2B IN UNTREATED ADVANCED INDOLENT B-CELL LYMPHOMA: 4-YEAR FOLLOW-UP STUDY (ICML 2025) - P2 | "Induction therapy consisted of rituximab biosimilar (Henliritux; 375 mg/m2 IV day 1) plus Peg-IFN-α2b (Pegberon; 135μg SC days 1, 8) every 21 days for 6 cycles. Rituximab biosimilar with Peg-IFN-α2b demonstrates durable efficacy and manageable toxicity in treatment-naïve iBCL, particularly in FL and MALT subtypes. The combination shows synergistic HBV suppression without reactivation risks. These results support further evaluation in larger randomized trials."

Metastases • B Cell Lymphoma • Extranodal Marginal Zone Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Lymphoplasmacytic Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma • Waldenstrom Macroglobulinemia • IFNA1

Palleon Pharmaceuticals and Henlius Collaborate to Advance Glycan Editing as a Treatment for Autoimmune Diseases (Businesswire) - "Palleon Pharmaceuticals...today announced a collaboration and license agreement with Shanghai Henlius Biotech, Inc. (2696.HK) to develop and commercialize Palleon’s first-in-class human sialidase enzyme therapeutic, E-602, in combination with Henlius’ self-developed HANLIKANG (rituximab) in patients with autoimmune diseases, including lupus nephritis (LN)....Under the terms of the agreement, Henlius received an exclusive China license to Palleon’s E-602. Palleon is eligible to receive up to $95.3 million in certain predetermined development and commercial milestones, in addition to royalties upon E-602 commercialization in China."

Licensing / partnership • Immunology • Lupus Nephritis

Henlius Maintains Patient-Centric Focus, Drives Sustainable Growth, and Accelerates Overseas Expansion in 2024 H1 (Henlius Press Release) - "In the first half of 2024, HANLIKANG, the first biosimilar launched in China...The company also plans to submit marketing applications for...HLX11 (pertuzumab biosimilar) in China and the U.S. in the second half of 2024."

China filing • FDA filing • Launch non-US • Oncology

Henlius Maintains Patient-Centric Focus, Drives Sustainable Growth, and Accelerates Overseas Expansion in 2024 H1 (Henlius Press Release) - "HANQUYOU (trastuzumab, trade name: HERCESSI in the U.S., Zercepac in Europe), HANSIZHUANG (serplulimab), and HANBEITAI (bevacizumab) recorded sales of RMB1.4743 billion, RMB677.8 million and RMB86.7 million, respectively. In addition, the company received sales revenues of RMB227.0 million and RMB13.6 million based on the collaboration with partners for HANLIKANG (rituximab)..."

Sales • Colorectal Cancer • Esophageal Cancer • Follicular Lymphoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • HER2 Positive Breast Cancer • Lung Non-Small Cell Squamous Cancer • Neuroendocrine Tumor • Small Cell Lung Cancer

Henlius Rituximab Receives Marketing Approval in Peru (Henlius Press Release) - "Recently, HANLIKANG (rituximab), independently developed and manufactured by Henlius, has been approved to be marketed in Peru under the trade name AUDEXA by the Dirección General de Medicamentos, Insumos y Drogas (DIGEMID). HANLIKANG is the third product that has been developed and manufactured by Henlius independently and approved for overseas marketing....The approval of HANLIKANG by DIGEMID in Peru is mainly based on the review of a series of data. The application dossier is mainly based on the information submitted to China’s National Medical Products Administration (NMPA) in the New Drug Application (NDA)."

Approval • Chronic Lymphocytic Leukemia • Non-Hodgkin’s Lymphoma • Rheumatoid Arthritis

Henlius to Showcase at BIO 2024 (Henlius Press Release) - "From June 3-6, 2024, the 2024 Biotechnology Innovation Organization International Convention...will be held in San Diego Convention Center, California, USA....During BIO 2024, the company will be at Booth #1719 with 5 launched products, including HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab for injection, trade name: HERCESSI in the U.S and Zercepac in Europe) and its innovative product HANSIZHUANG, the world’s first anti-PD-1 mAb for the first-line treatment of small cell lung cancer."

Clinical • Breast Cancer • Chronic Lymphocytic Leukemia • Hematological Malignancies • HER2 Breast Cancer • HER2 Positive Breast Cancer • Lung Cancer • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Cell Lung Cancer • Solid Tumor

Long-term outcomes with HLX01 (HanliKang), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study. (PubMed, BMC Cancer) - "Patients were randomised to either rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or HLX01 plus CHOP (H-CHOP) every 21 days for up to six cycles. Treatment outcomes did not differ between groups regardless of IPI score and were consistent with the primary analysis. H-CHOP and R-CHOP provided no significant difference in 5-year OS or PFS in previously untreated patients with low or low-intermediate risk DLBCL."

Journal • P3 data • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20

Henlius Xuhui Facility Passes Colombian GMP Inspection for HANLIKANG (Henlius Press Release) - "Shanghai Henlius Biotech...announces that recently, it has received the resolution of the Colombian National Food and Drug Surveillance Institute (the 'INVIMA') to grant it the GMP certification, pursuant to which the company’s manufacturing site Xuhui Facility has successfully passed the GMP inspection by the INVIMA for the related production lines of HANLIKANG and meets Colombian GMP standards. INVIMA certifies quality management system by adopting WHO standards and wins high recognition in South America. The GMP certification by Colombia, along with the GMP certification by Brazil, brings HANLIKANG a step further to South American countries."

Commercial • Chronic Lymphocytic Leukemia • Non-Hodgkin’s Lymphoma

Henlius Xuhui Facility Passes PIC/S Member ANVISA GMP Inspection for HANLIKANG and HANQUYOU (Henlius Press Release) - "Shanghai Henlius Biotech, Inc...announces that recently, it has received GMP certificates issued by the Brazilian National Health Surveillance Agency (Portuguese: Agência Nacional de Vigilância Sanitária,'ANVISA'), one of the Pharmaceutical Inspection Co-operation Scheme (PIC/S) participating members, indicating that its Xuhui Facility passes the GMP inspection of the drug substance (DS) and drug product (DP) production lines of its rituximab HANLIKANG and trastuzumab HANQUYOU (trade name in Europe: Zercepac^®; trade names in Australia: Tuzucip^® and Trastucip^®) by ANVISA and meets PIC/S GMP standards. This is the first time that the production lines of HANLIKANG have passed GMP inspection conducted by an overseas authority."

Non-US regulatory • Breast Cancer • Chronic Lymphocytic Leukemia • Gastric Cancer • Gastrointestinal Cancer • Hematological Malignancies • HER2 Breast Cancer • HER2 Positive Breast Cancer • Immunology • Inflammation • Inflammatory Arthritis • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Rheumatoid Arthritis • Solid Tumor

Henlius 2023 H1 Results: Achieved record profits and RMB2.5 billion revenues, opening a new chapter of high-quality growth (PRNewswire) - "In the first half of 2023, Henlius achieved a total sales revenue at a record high of approximately RMB2.1529 billion increased by 82.2% YoY, with its ever-increasing self-supporting capability, driving the company into a new stage of sustainable development. The company has established a professional and efficient commercial team to build a business presence in the China market and drive the market penetration on the in-house products HANQUYOU, HANSIZHUANG and HANBEITAI (bevacizumab). In the first half of 2023, these core products of the company gained sales revenue of RMB1.2767 billion, RMB556.3 million and RMB44.9 million, respectively. In addition, the company received a profit-sharing of RMB254.1 million and RMB20.8 million for HANLIKANG (rituximab)..."

Commercial • Sales • Breast Cancer • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

Disease Characteristics and Treatment Outcomes with HLX01: A Real-World Study in Patients with B-Cell Non-Hodgkin Lymphoma in China (ASH 2022) - "Rituximab (R) has changed the treatment landscape of NHL; approvals of rituximab biosimilars have improved access to and the affordability of this treatment (Mohammed et al., J Blood Med 2019).HLX01 is the first rituximab biosimilar approved for the treatment of NHL and chronic lymphocytic leukemia in China. The most common AEs were decreased white blood cell count (3.9%), decreased neutrophil count (3.5%), and nausea/vomiting (3.3%).Conclusion s DLBCL is the most common subtype in HLX01-treated patients with B-cell NHL in China. HLX01 showed clinical benefits with favorable safety profiles in patients with B-cell NHL subtypes in a real-world setting"

Clinical • Real-world evidence • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Rituximab Biosimilar Combined with Pegylated Interferon α-2b in Patients with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Multicenter, Single-Arm, Phase II Study (ASH 2021) - P2 | "During induction phase, pts received rituximab biosimilar (Henliritux ® Shanghai Henlius Biotech) 375 mg/m 2 intravenous infusion on d1. Peg-IFN-α2b (Pegberon ® , Xiamen Amoytop Biotech) was given at a dose of 135ug, subcutaneously, on d1,8...Simultaneously, CHB pts orally treated with entecavir continuously... Rituximab biosimilar plus pegylated interferon α-2b provided favorable response in newly diagnosed advanced iBCL and was well tolerated. No hepatitis B virus reactivation was observed. Further investigation is warranted."

Clinical • P2 data • Anemia • Fatigue • Hematological Malignancies • Hepatitis B • Hepatology • Indolent Lymphoma • Infectious Disease • Inflammation • Lymphoma • Marginal Zone Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia • IFNA1

A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma (clinicaltrials.gov) - P=N/A | N=100 | Recruiting | Sponsor: Zhengzhou University

New trial • Hematological Malignancies • Mantle Cell Lymphoma • Oncology • Solid Tumor

Rituximab biosimilar HLX01 versus reference rituximab in the treatment of diffuse large B-cell lymphoma: Real-world clinical experience. (PubMed, J Oncol Pharm Pract) - "HLX01 is a suitable replacement for reference rituximab in the treatment of diffuse large B-cell lymphoma and is relatively inexpensive, thereby reducing the economic burden of patients. Nevertheless, the conclusion of this study still needs to be further validated by large-sample real-world data and explored for HLX01 in other indications, such as follicular lymphoma."

Journal • Real-world evidence • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Efficacy and safety of HLX01 in patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a phase 3 study. (PubMed, Arthritis Res Ther) - P3 | "HLX01 plus methotrexate improved clinical outcomes compared with placebo in Chinese patients with rheumatoid arthritis who had inadequate responses to methotrexate. This treatment regimen was well tolerated, showing comparable safety profiles to placebo."

Journal • P3 data • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology